AIkido Pharma (AIKI) Competitors

Data Knights Acquisition has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

Data Knights Acquisition is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

In the previous week, Data Knights Acquisition's average media sentiment score of 0.00 equaled AIkido Pharma'saverage media sentiment score.

35.3% of Data Knights Acquisition shares are held by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are held by institutional investors. 45.7% of Data Knights Acquisition shares are held by insiders. Comparatively, 8.6% of AIkido Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Data Knights Acquisition's return on equity of 0.00% beat AIkido Pharma's return on equity.

ImageneBio has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

AIkido Pharma has lower revenue, but higher earnings than ImageneBio. AIkido Pharma is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are held by institutional investors. 5.9% of ImageneBio shares are held by insiders. Comparatively, 8.6% of AIkido Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, ImageneBio's average media sentiment score of 1.94 beat AIkido Pharma's score of 0.00 indicating that ImageneBio is being referred to more favorably in the media.

ImageneBio currently has a consensus price target of $26.50, indicating a potential upside of 354.55%. Given ImageneBio's stronger consensus rating and higher possible upside, equities analysts plainly believe ImageneBio is more favorable than AIkido Pharma.

AIkido Pharma's return on equity of -18.21% beat ImageneBio's return on equity.

In the previous week, Cumberland Pharmaceuticals had 7 more articles in the media than AIkido Pharma. MarketBeat recorded 7 mentions for Cumberland Pharmaceuticals and 0 mentions for AIkido Pharma. Cumberland Pharmaceuticals' average media sentiment score of 0.32 beat AIkido Pharma's score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Cumberland Pharmaceuticals has higher revenue and earnings than AIkido Pharma. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

AIkido Pharma has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -6.37%. Cumberland Pharmaceuticals' return on equity of 5.04% beat AIkido Pharma's return on equity.

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AIkido Pharma has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500.

AIkido Pharma has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Comparatively, 55.3% of Dominari shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AIkido Pharma has a net margin of 0.00% compared to Dominari's net margin of -18.22%. AIkido Pharma's return on equity of -18.21% beat Dominari's return on equity.

AIkido Pharma has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

In the previous week, Dominari had 3 more articles in the media than AIkido Pharma. MarketBeat recorded 3 mentions for Dominari and 0 mentions for AIkido Pharma. Dominari's average media sentiment score of 0.84 beat AIkido Pharma's score of 0.00 indicating that Dominari is being referred to more favorably in the news media.